Hepatocellular carcinoma (HCC), a prevalent primary liver cancer, poses a significant global health challenge due to its insidious nature and high mortality rate. Despite extensive research, the prognosis for HCC remains poor, particularly for those diagnosed at advanced stages. This article delves into the evaluation of treatment strategies for advanced HCC, focusing on the combination of transarterial chemoembolization (TACE) with lenvatinib and pembrolizumab.
The Battle Against Advanced HCC: Unveiling Treatment Options
HCC therapeutic approaches are guided by staging systems and treatment guidelines. Among the various systems, the Barcelona Clinic Liver Cancer (BCLC) system stands out for its comprehensive consideration of liver function, tumor stage, and physical status. For BCLC stage C, characterized by portal vein invasion (PVI) and extrahepatic spread (ES), guidelines recommend TACE, targeted therapies, and immunotherapy.
Historically, sorafenib has been the sole recommended first-line treatment for advanced HCC. However, despite its use, patient outcomes remain suboptimal, with limited improvements in overall survival (OS). The emergence of novel targeted drugs and immune checkpoint inhibitors, such as lenvatinib, regorafenib, and nivolumab, offers new hope for advanced HCC patients.
The Evolution of Treatment: A Combination Approach
The IMbrave150 study demonstrated that the combination of atezolizumab and bevacizumab significantly outperformed sorafenib as a first-line treatment for unresectable HCC, with a progression-free survival (PFS) of 6.8 months. Additionally, the LEAP-012 study showed that TACE combined with lenvatinib and pembrolizumab improved PFS and trended towards better OS in patients with intermediate-stage HCC.
Unraveling the Role of PIVKA-II: A Valuable Biomarker
PIVKA-II, a serum biomarker, has gained attention for its potential in HCC diagnosis and prognosis evaluation. Studies suggest that PIVKA-II complements AFP, improving diagnostic accuracy, especially in AFP-negative cases. Furthermore, PIVKA-II levels correlate with tumor progression and surgical outcomes, making it a valuable tool for treatment evaluation.
A Retrospective Study: Assessing Treatment Efficacy and Safety
This retrospective study aimed to evaluate the effectiveness and safety of two treatment regimens for patients with BCLC C advanced HCC. The study included 260 patients, with 126 receiving TACE (TL) therapy and 134 receiving TACE-lenvatinib-pembrolizumab (TPB) therapy. The results showed significant improvements in median PFS and OS for the TPB group compared to the TL group.
The Impact of PIVKA-II: A Negative Correlation with OS
After three months of treatment, the TPB group exhibited a significant decrease in PIVKA-II levels, suggesting a negative correlation with OS. This finding highlights the importance of PIVKA-II as a biomarker for HCC prognosis.
Survival Benefits and Predictive Factors
Univariate analysis revealed that younger patients (≤65 years) in the TPB group had prolonged PFS compared to older patients. Additionally, the presence of hand-foot syndrome was associated with increased OS and PFS in the experimental group.
Toxicity and Safety Profile
The safety analysis included all 260 patients, and the treatment was generally well-tolerated, with no grade 4 or 5 adverse reactions observed within three months of lenvatinib and pembrolizumab administration. The most common adverse events were proteinuria and hypertension, occurring in approximately 50% of patients.
Discussion and Limitations
TACE is a crucial treatment modality for unresectable HCC, and its combination with targeted and immunotherapeutic drugs shows promise. The study findings suggest that the combination of TACE, lenvatinib, and pembrolizumab offers superior clinical outcomes for BCLC stage C HCC. However, the study had limitations, including its retrospective nature and a limited number of cases, which may impact the generalizability of the results.
Conclusion and Future Directions
The combination of TACE with lenvatinib and pembrolizumab was found to be safe and well-tolerated for advanced HCC patients, with improved OS and PFS compared to TACE monotherapy. While the study provides valuable insights, larger prospective studies are needed to further validate these findings and guide optimal treatment strategies for advanced HCC.
